Overview

Glucagon's Cardiovascular Effects With and Without Beta-blocker-induced Cardioinhibition

Status:
Completed
Trial end date:
2019-10-01
Target enrollment:
0
Participant gender:
Male
Summary
This trial investigates effects of a glucagon bolus injection on heart rate, blood pressure and cardiac output during beta-blocker-induced cardiodepression. Furthermore, the effects of two different doses of intravenous glucagon on hemodynamic parameters are explored.
Phase:
Phase 4
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
University Hospital Bispebjerg and Frederiksberg
Treatments:
Adrenergic beta-Antagonists
Esmolol
Glucagon
Glucagon-Like Peptide 1
Pharmaceutical Solutions
Criteria
Inclusion Criteria:

- Healthy male determined by investigator, based upon physical examination, medical
history, ECG, vital signs and laboratory results

- Body mass index (BMI) ≥ 18.5 and ≤ 29.9 kg/m2 and body weight between 50 and 100 kg,
inclusive, at screening visit.

Exclusion Criteria:

- Abnormal blood levels of sodium, potassium, creatinine, alanine transaminase (ALT),
alkaline phosphatase, albumin, bilirubin, hemoglobin, HbA1c, cholesterol fractions.

- Bradycardia (<45 beats per minute)

- Hypotension (systolic blood pressure < 100 mmHg)

- Second or third degree atrioventricular conduction delay

- Sick sinus syndrome

- Any heart disease or hypertension

- Pheochromocytoma

- Allergy to any active or inactive ingredient contained in investigatory medicines or
tools.

- Raynaud's syndrome

- Prinzmetal's angina

- Diabetes

- Pulmonary disease

- Pheochromocytoma

- Any contraindication against investigatory medicines or tools.